Fundraising Fox
🦊/People
Sign in

Charles Dunn

Investor

Principal at SV Health Investors Β· Board director at Imbria Pharmaceuticals

London

Writes $100K – $5M checks Β· typically $1.5M

Find your path to Charles

332 people in our graph share verified history with Charles β€” schools, employers, funds. One of them is your warm intro.

Issi RozenunlockedCharles: together at Mestag Therapeutics (2021–2026)
Γ—4Charles: together at UCL
Γ—3Charles: together at ICAEW
Charles: together at Mestag Therapeutics

About

Charles Dunn joined SV Health Investors in 2018 as a Principal on the biotech team, where he helps form and fund companies developing new medicines across early creation to later-stage public and private opportunities. Before SV he qualified as an ACA after three years at Deloitte serving Life Sciences clients, and has an academic background in human genetics and molecular biology from UCL.

ContactΒ· self-published, not guessed

Invests in

Biotech

Board director at Imbria Pharmaceuticals

Intro paths

β†’

In turn, Charles can intro founders to Imbria Pharmaceuticals's investors below.

Imbria Pharmaceuticals's investors Β· 3

Catalio Capital ManagementNew York Β· since 2025RA CapitalBoston Β· since 2025SV Health InvestorsBoston Β· $1M – $20M checks Β· since 2025

Experience

  1. SV Health InvestorsPrincipalcurrent2023 β€” present
  2. SV Health InvestorsVice President2022 β€” 2023
  3. SV Health InvestorsSenior Investment Associate2021 β€” 2022
  4. SV Health InvestorsInvestment Associate2019 β€” 2021London, United Kingdom
  5. SV Health InvestorsInvestment Analyst2018 β€” 2019London, United Kingdom
  6. Draig TherapeuticsMember Board of Directors & Founding Investorcurrent2024 β€” present
  7. Imbria PharmaceuticalsMember Board of Directorscurrent2023 β€” present
  8. Imbria PharmaceuticalsBoard Observer2020 β€” 2023
  9. Mestag TherapeuticsMember Board of Directorscurrent2023 β€” present
  10. Mestag TherapeuticsBoard Observer & Founding Team2020 β€” 2023
  11. PulmocideBoard Observercurrent2020 β€” present
  12. Autifony TherapeuticsBoard Observercurrent2019 β€” present
  13. Enara BioBoard Observer2020 β€” 2024
  14. ZarodexBoard Observer2019 β€” 2021
  15. Deloitte UKAssistant Manager2016 β€” 2017Cambridge, United Kingdom
  16. Deloitte UKSenior Associate (Entrepreneurial Business)2015 β€” 2016
  17. Deloitte UKAssociate (Entrepreneurial Business)2014 β€” 2015

Deals Β· 1

Draig TherapeuticsLed round

via SV Health Investors

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Autifony TherapeuticsEnaraBioImbria PharmaceuticalsMestag TherapeuticsPulmocide

Per the firm's website.

Colleagues at SV Health Investors

A.J. Rossi
Partner at SV Health Investors
Aaron Sandoski
MCF Partner at SV Health Investors
Alan Foster
Managing Director at TeleSoft.AI
Alex Badamchi-Zadeh
Vice President at SV Health Investors
Amer Ramzan
Managing Partner at Promentum Equity Partners
Andrew Cappetta
Senior Associate at SV Health Investors
Brent Faduski
CFO, CCO and Partner at SV Health Investors
Christian Jung
Partner at Dementia Discovery

Network6

Alex Badamchi-Zadeh
Vice President at SV Health Investors
Christian Jung
Partner at Dementia Discovery
Darren Black
Partner at SV Health Investors
Dirk Landgraf
Principal at SV Health Investors
Emily Gaudiano
Associate at SV Health Investors
Eugene Hill
Chairman at SV Health Investors

Investors connected to Charles in public investor directories β€” a warm-intro map.

Frequently asked questions

Who is Charles Dunn?
Charles Dunn joined SV Health Investors in 2018 as a Principal on the biotech team, where he helps form and fund companies developing new medicines across early creation to later-stage public and private opportunities. Before SV he qualified as an ACA after three years at Deloitte serving Life Sciences clients, and has an academic background in human genetics and molecular biology from UCL.
Where does Charles Dunn work?
Charles Dunn is Principal at SV Health Investors and Board director at Imbria Pharmaceuticals.
What does Charles Dunn invest in?
Charles Dunn invests in Biotech.
What check size does Charles Dunn write?
Charles Dunn typically writes checks of $100K – $5M.
What boards does Charles Dunn sit on?
Charles Dunn holds tracked board seats at Autifony Therapeutics, EnaraBio, Imbria Pharmaceuticals, Mestag Therapeutics, Pulmocide.
What companies has Charles Dunn invested in?
Investments tracked here include Draig Therapeutics.
Where did Charles Dunn go to school?
Charles Dunn studied at UCL (MSci, Human/Medical Genetics); ICAEW (ACA); Hills Road Sixth Form College.
Does Charles Dunn lead rounds?
Yes β€” Charles Dunn has led 1 tracked investment.

Same school

Shared employers